Clinical perspective, offered as context rather than as advice. It is worth asking what the claim would look like if it were false. If nothing would look different, it is not a claim about the world and no amount of discussion will settle it.
Dr.MetabolicMD said:It is worth asking what the claim would look like if it were false.
This matches mine closely enough to be worth saying so out loud.
Dr.MetabolicMD said:It is worth asking what the claim would look like if it were false.
There is a second half to this that has not been said yet. Steady state is faster than people expect: half-life about five days, so you are at plateau in roughly three to four weeks rather than five. That matters when you are deciding whether a dose step has finished expressing itself.
Worth separating that from tirzepatide, which this thread keeps folding into the same question. They behave differently and the advice does not transfer.
Community-driven peptide testing and vendor rating platform. Transparent results. Unbiased analysis. Trusted by thousands.
View ResultsAdding the numbers, since they settle part of this. For anyone reading later: the numbers in this thread are worth checking against a primary source before you act on them, including mine. Half the figures circulating in this community trace back to a secondary summary that dropped a qualifier.
Following on from Dr.MetabolicMD — and this may be the naive question:
How much of the tirzepatide advantage is the GIP component and how much is simply that the dose ladder goes higher in receptor-occupancy terms?